Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below provides a snapshot of ...

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.The company traded as ...

NEOGENOMICS ($NEO) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of $0.04 per share, beating estimates of $0.03 by $0.01 ...

NeoGenomics Inc (NEO) reports robust revenue growth and improved margins, while navigating challenges in the pharma segment and ongoing litigation.